433 related articles for article (PubMed ID: 26852185)
41. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease.
Arendt BM; Teterina A; Pettinelli P; Comelli EM; Ma DWL; Fung SK; McGilvray ID; Fischer SE; Allard JP
Nutrition; 2019 Jun; 62():100-107. PubMed ID: 30870804
[TBL] [Abstract][Full Text] [Related]
42. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Chen G; Ni Y; Nagata N; Xu L; Ota T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
[TBL] [Abstract][Full Text] [Related]
43. Effect of resveratrol on experimental non-alcoholic steatohepatitis.
Heebøll S; Thomsen KL; Clouston A; Sundelin EI; Radko Y; Christensen LP; Ramezani-Moghadam M; Kreutzfeldt M; Pedersen SB; Jessen N; Hebbard L; George J; Grønbæk H
Pharmacol Res; 2015; 95-96():34-41. PubMed ID: 25814186
[TBL] [Abstract][Full Text] [Related]
44. The diagnosis and treatment of non-alcoholic fatty liver disease.
Altinbas A; Sowa JP; Hasenberg T; Canbay A
Minerva Gastroenterol Dietol; 2015 Sep; 61(3):159-69. PubMed ID: 26080905
[TBL] [Abstract][Full Text] [Related]
45. Comparative study of the modulation of fructose/sucrose-induced hepatic steatosis by mixed lipid formulations varying in unsaturated fatty acid content.
Siddiqui RA; Xu Z; Harvey KA; Pavlina TM; Becker MJ; Zaloga GP
Nutr Metab (Lond); 2015; 12():41. PubMed ID: 26583036
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of vitamin D supplement in children with nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis.
Liu J; Wang T; Chen J; Zhang Y; Yin X; Fan X; Chen Q
Medicine (Baltimore); 2020 Jul; 99(31):e20960. PubMed ID: 32756082
[TBL] [Abstract][Full Text] [Related]
47. Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials.
Amanullah I; Khan YH; Anwar I; Gulzar A; Mallhi TH; Raja AA
Postgrad Med J; 2019 Nov; 95(1129):601-611. PubMed ID: 31434683
[TBL] [Abstract][Full Text] [Related]
48. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
Wah Kheong C; Nik Mustapha NR; Mahadeva S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
[TBL] [Abstract][Full Text] [Related]
49. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
Kelley NS
Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
[TBL] [Abstract][Full Text] [Related]
50. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
Barchetta I; Cimini FA; Cavallo MG
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
[TBL] [Abstract][Full Text] [Related]
51. Effects of vitamin D supplementation on liver fibrogenic factors in non-alcoholic fatty liver patients with steatohepatitis: study protocol for a randomized clinical trial.
Ebrahimpour-Koujan S; Sohrabpour AA; Foroughi F; Alvandi E; Esmaillzadeh A
Trials; 2019 Mar; 20(1):153. PubMed ID: 30832722
[TBL] [Abstract][Full Text] [Related]
52. Effects of Delta-tocotrienol Supplementation on Liver Enzymes, Inflammation, Oxidative stress and Hepatic Steatosis in Patients with Nonalcoholic Fatty Liver Disease.
Pervez MA; Khan DA; Ijaz A; Khan S
Turk J Gastroenterol; 2018 Mar; 29(2):170-176. PubMed ID: 29749323
[TBL] [Abstract][Full Text] [Related]
53. Vitamin D supplementation for the treatment of non-alcoholic fatty liver disease: A randomized double blind placebo controlled trial.
Dabbaghmanesh MH; Danafar F; Eshraghian A; Omrani GR
Diabetes Metab Syndr; 2018 Jul; 12(4):513-517. PubMed ID: 29588137
[TBL] [Abstract][Full Text] [Related]
54. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
[TBL] [Abstract][Full Text] [Related]
55. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
Spahis S; Alvarez F; Ahmed N; Dubois J; Jalbout R; Paganelli M; Grzywacz K; Delvin E; Peretti N; Levy E
J Nutr Biochem; 2018 Aug; 58():28-36. PubMed ID: 29864682
[TBL] [Abstract][Full Text] [Related]
56. Negative association between antioxidant vitamin intake and non-alcoholic fatty liver disease in Chinese non-diabetic adults: mediation models involving superoxide dismutase.
Ma C; Liu Y; He S; Zeng J; Li P; Ma C; Ping F; Zhang H; Xu L; Li W; Li Y
Free Radic Res; 2020 Sep; 54(8-9):670-677. PubMed ID: 32985285
[TBL] [Abstract][Full Text] [Related]
57. Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes.
Zabihi NA; Pirro M; Johnston TP; Sahebkar A
Curr Pharm Des; 2017; 23(7):969-982. PubMed ID: 27748192
[TBL] [Abstract][Full Text] [Related]
58. Effect of Fish Oil Supplementation on Hepatic and Visceral Fat in Overweight Men: A Randomized Controlled Trial.
Parker HM; Cohn JS; O'Connor HT; Garg ML; Caterson ID; George J; Johnson NA
Nutrients; 2019 Feb; 11(2):. PubMed ID: 30813440
[TBL] [Abstract][Full Text] [Related]
59. Role of vitamin E in nonalcoholic fatty liver disease.
Nagashimada M; Ota T
IUBMB Life; 2019 Apr; 71(4):516-522. PubMed ID: 30592129
[TBL] [Abstract][Full Text] [Related]
60. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
